A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

Biological Psychiatry

Volumn 51, Issue 5, 2002, Pages 349-357

  Friedman, Joseph I ^a,c   Adler, David N ^b   Howanitz, Evelyn ^a   Harvey, Philip D ^a   Brenner, Grant ^a   Temporini, Humberto ^a   White, Leonard ^b   Parrella, Michael ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Pilgrim Psychiatric Center   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

Acetylcholine; Clinical trial; Cognitive; Donepezil; Schizophrenia

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; LIGAND; NICOTINIC RECEPTOR; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MEMORY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TOBACCO DEPENDENCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0036501411     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01342-7     Document Type: Article

References (68)

1. Normalization of auditory physiology by cigarette smoking in schizophrenic patients
2. Schizophrenia, sensory gating, and nicotinic receptors
3. The effects of physostigmine and scopolamine on recognition memory in monkeys
4. Memory impairment in schizophrenia: A meta-analysis
5. Diversity of nicotinic acetylcholine receptors in rat brain: Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release
6. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology
7. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine
8. Deficits in passive avoidance learning following atropine in the developing rat
9. Effects of xanomaline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
10. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia
11. Postmortem central catecholamines and ante mortem cognitive impairment in elderly schizophrenics and controls
12. Continuous icv infusion of scopolamine impairs sustained attention of rhesus monkeys
13. Treatment of tardive dyskinesia with donepezil
14. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients
15. Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation
16. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis
17. Dopamine in schizophrenia: A review and reconceptualization
18. Memory and cognitive function in man. Does the cholinergic system have a specific role?
19. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia
20. Upregulation of surgace alpha4beta2 nicotine receptors initiated by receptor desensitization after chronic exposure to nicotine
21. Acetylcholine activates an α-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells
22. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
23. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia
24. A behavioral analysis of degree of impairment and ease of shifting to new responses in a Weigl-type card sorting problem
25. Does risperidone improve verbal working memory in treatment resistant schizophrenia?
26. Cortical cholinergic markers in schizophrenia
27. Cognitive deficits without a cholinergic cause. Choline acetyltransferase activity in the parietal cortex of 95 elderly schizophrenics
28. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
29. Prevalence of smoking among psychiatric outpatients
30. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions
31. Physostigmine and cognition in schizotypal personality disorder
32. On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls
33. Nicotinic receptor function in schizophrenia
34. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation
35. Chronic nicotine effects on working and reference memory in the 16-arm radial maze: Interactions with D1 agonist and antagonist drugs
36. Development of nicotinic drug therapy for cognitive disorders
37. Cholinergic gating of response to auditory stimuli in rat hippocampus
38. New approach to drug therapy in Alzheimer's disease
39. Allosteric sensitization of nicotinic receptors by galantamine, and new treatment strategy for Alzheimer's disease
40. Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction
41. The effects of AMPA-induced lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on spatial delayed non-matching to sample and spatial learning in the water maze
42. Investigation about an influence of physostigmine on schizophrenic symptoms
43. Attentional functions of the forebrain cholinergic systems: Effects of intraventricular hemicholinium, physostigmine, basal cortical lesions and intracortical grafts on a multiple choice serial reaction time task
44. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study
45. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes
46. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020)
47. Postmortem studies in schizophrenia
48. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure
49. High marker-density analyses of the α7-nicotine cholinergic receptor subunit (CHRNA7) gene region on chromosome 15q13-q14 and 5′ RACE cloning of fragments specific to CHRNA7 or its partial duplication
50. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates
51. Comparative effects of ibotenic acid and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: Further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes
52. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Donepezil study group
53. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil study group
54. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses
55. Enhanced performance of spatial and visual memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys
56. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia
57. Agonist responses of neuronal nicotinic are potentiated by a novel class of allosterically acting ligands
58. The boundaries of schizophrenia
59. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020) and related compounds
60. Characterization of a novel muscarinic receptor agonist, YM796: Comparison with cholinesterase inhibitors in in-vivo pharmacological studies
61. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients
62. Distribution of nicotinic acetylcholine receptor α7 and β2 submits on cultured hippocampal neurons